Table 2 MSCs criteria reported by included studies.
Author (Year) | Does the study report MSCS criteria? | Were MSCs purchased or supplied? | Plastic adherence? | Positive markers | Negative markers | Differentiation capability | Cell expansion media | Passage number |
|---|---|---|---|---|---|---|---|---|
Cho et al. (2016)34 | No (only plastic adherence) | Not reported | Yes | Not reported | Not reported | Not reported | DMEM-low glucose, 10% FBS, penicillin, streptomycin | Not reported |
Ding et al. (2015)22 | Yes | No | Yes | CD 29, CD 44, CD 90, CD 105 | CD54 | Osteoblasts, chondrocytes, adipocytes | Minimum essential medium-α, 10% FBS, penicillin, streptomycin | 4–5 |
Ding et al. (2017)23 | Yes | No | Yes | CD 29, CD 44, CD 90, CD 105 | CD 45 | Osteoblasts, chondrocytes, adipocytes | Minimum essential medium-α, 10% FBS, penicillin, streptomycin | 4–5 |
Kim et al. (2012)35 | Yes | No | Yes | Oct-4, SSEA-4, HLA-AB, CD 73, CD 105 | HLA-DR, CD 14, CD 34, CD 45 | Respiratory epithelium, osteoblasts, chondrocytes, adipocytes | Not reported | 5 |
Larpthaveesarp et al. (2021)37 | Yes | Yes (Creative Bioarray, Shirley, NY) | Not reported | CD 29, CD 44, CD 90, and CD 105 | CD11b, CD 34, CD 45 | Osteogenic, chondrogenic, adipogenic lineages | Not reported | Not reported |
Lee et al. (2010)36 | Yes | No | Yes | CD 73, CD 105 | CD 14, CD 34, CD 45 | Not reported | 10% DMEM-low glucose, 10% FBS, 1% antibiotic-antimycotic solution | Within 5 |
Li et al. (2014)24 | No (only plastic adherence) | No | Yes | Not reported | Not reported | Not reported | DMEM/F12, 10% FBS | 4–6 |
Ohshima et al. (2015)40 | No (only plastic adherence) | No | Yes | Not reported | Not reported | Not reported | α-MEM, 10% FBS, penicillin, streptomycin | 4–5 |
Sakai et al. (2018)41 | Yes | No | Yes | CD 73, CD 90 | CD 45, CD 106 | Not reported | DMEM, 10% heat-inactivated FBS, L-glutamine, penicillin, streptomycin | 3 |
van Velthoven et al. (2017)38 | Yes | GIBCO | Not reported | CD 29, CD 44, CD 90, CD 106 | Myeloid and hematopoietic cell lineage-specific antigens | Not reported | Not reported | Not reported |
van Velthoven et al. (2013)33 | Yes | GIBCO | Yes | CD 29, CD 44, CD 90, CD 106 | Myeloid and hematopoietic cell lineage-specific antigens | Not reported | DMEM | Not reported |
van Velthoven et al. (2010)29 | Yes | The Jackson Laboratory | Yes | Sca-1, MHC-I, CD 29, CD 44, CD 90 | Myeloid and hematopoietic cell lineage-specific antigens | Not reported | DMEM, 15% FBS | Not reported |
van Velthoven et al. (2010)31 | Yes | The Jackson Laboratories | Yes | Sca-1, MHC-I, CD 29, CD 44, CD 90 | Myeloid and hematopoietic cell lineage-specific antigens | Not reported | DMEM, 15% FBS | Not reported |
van Velthoven et al. (2010)32 | Yes | The Jackson Laboratory | Yes | Sca-1, MHC-I, CD 29, CD 44, CD 90 | Myeloid and hematopoietic cell lineage-specific antigens | Adipocytes, osteocytes, chondrocytes | DMEM, 15% FBS | Not reported |
van Velthoven et al. (2012)30 | Yes | The Jackson Laboratories | Yes | Sca-1, MHC-I, CD 29, CD 44, CD 90 | Myeloid and hematopoietic markers | Not reported | Not reported | Not reported |
Wei et al. (2015)39 | Yes | No | Yes | CD 105, CD 73 | CD 34, CD 45 | Not reported | DMEM, 15% FBS | 3–5 |
Xia et al. (2010)25 | Yes | No | Yes | CD 29, CD 44, CD 105 | CD 34, CD 45 | Osteoblasts, chondrocytes, adipocytes | DMEM, 20% FBS, penicillin streptomycin, L-glutamine | 10 |
Yang et al. (2020)28 | No (only plastic adherence) | No | Yes | Not reported | Not reported | Not reported | Not reported | Not reported |
Zhang et al. (2014)26 | Yes | No | Yes | CD 73, CD 105, CD 90 | CD 14, CD 34, CD 45, CD 79a | Not reported | StemPro MSCSserum-free medium, 10% FBS, penicillin, streptomycin | 3 |
Zhou et. al. (2015)27 | Yes | Chongqing stem cell bank | Yes | HLA-ABC, CD 29, CD 44, CD 90, CD 105 | HLA-DR, CD 34, CD 45 | Neural differentiation | DMEM/F12, 10% FBS, penicillin, streptomycin | 5–10 |
